


BTS/NICE/SIGN 2024 Guidelines (NG245) for the pharmacological management of asthma in people aged 12 years and older¹



*As stated by Asthma + Lung UK: the use of as needed ICS/Formoterol may be suitable for patients where any one of the following apply:²

1. Asthma symptoms present occasionally (e.g less than twice a month)
2. Only need managing asthma at certain times of the year e.g. pollen season
3. If occasional allergens trigger asthma symptoms, or
4. Need help managing symptoms when exercising

Uncontrolled asthma: Any exacerbation requiring oral corticosteroids or frequent regular symptoms (such as using reliever inhaler 3 or more days a week or nighttime waking 1 or more times a week)¹

Adapted from BTS/NICE/SIGN 2024 Guideline - please see full guideline for all information

This guideline does not recommend specific products - Fobumix Easyhaler® is an option for your patients in MART and AIR.
Take into account and try to address the possible reasons for uncontrolled asthma before starting or adjusting medicines.

ICS, inhaled corticosteroid; **LABA**, long-acting beta2 agonist; **LAMA**, long-acting muscarinic receptor antagonist; **LTRA**, leukotriene receptor antagonist; **MART**, maintenance and reliever therapy (using ICS/formoterol combination inhalers); **SABA**, short-acting beta2 agonist.

Existing diagnosis of asthma on the treatment pathway recommended by previous NICE and BTS/SIGN guidelines¹

Patients on SABA Only

Offer low-dose AIR therapy with ICS/Formoterol (to be taken as needed)

Fobumix Easyhaler® 160/4.5



If uncontrolled asthma on **SABA** as well as either:

- Low-dose **ICS**
- Low-dose **ICS/LABA**
- Low-dose **ICS plus LTRA**
- Low-dose **ICS/LABA plus LTRA**

Consider

Low-dose MART with Fobumix Easyhaler®

Fobumix Easyhaler® 80/4.5
Fobumix Easyhaler® 160/4.5



If uncontrolled asthma on **SABA** as well as either:

- Moderate dose **ICS**
- Moderate dose **ICS/LABA**
- Moderate dose **ICS plus LTRA and/or LAMA**
- Moderate dose **ICS/LABA plus LTRA and/or LAMA**

Consider

Moderate dose MART with Fobumix Easyhaler®

Fobumix Easyhaler® 160/4.5



If asthma is uncontrolled on **high-dose ICS**

Refer people to a specialist in asthma care

Fobumix Easyhaler® Indication:

Asthma: Regular treatment of asthma where the use of a combination (inhaled corticosteroid and long-acting beta-2-adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting beta-2-adrenoceptor agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting beta-2-adrenoceptor agonists.

Fobumix Easyhaler® 80/4.5mcg: indicated for maintenance therapy in patients ≥6 years of age, and MART in patients ≥12 years of age.

Fobumix Easyhaler® 160/4.5mcg: indicated for reliever therapy (as-needed, AIR) in mild asthma, maintenance therapy and MART in patients ≥12 years of age.

Fobumix Easyhaler® 320/9mcg: indicated for maintenance therapy only in patients ≥12 years of age.

Note: Fobumix Easyhaler® 80/4.5mcg is not appropriate in patients with severe asthma.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300

References

1. BTS/NICE/SIGN Guidelines 2024. Asthma: diagnosis, monitoring and chronic asthma management. Revised November 2024. <https://www.nice.org.uk/guidance/ng245>. Accessed: May 2025.
2. Asthma+Lung UK. AIR (anti-inflammatory reliever). Available at: <https://www.asthmaandlung.org.uk/symptoms-tests-treatments/treatments/air>. Accessed: May 2025

Uncontrolled asthma: Any exacerbation requiring oral corticosteroids or frequent regular symptoms (such as using reliever inhaler 3 or more days a week or nighttime waking 1 or more times a week)¹

Adapted from BTS/NICE/SIGN 2024 Guideline - please see full guideline for all information

This guideline does not recommend specific products – Fobumix Easyhaler® is an option for your patients in MART and AIR.
Take into account and try to address the possible reasons for uncontrolled asthma before starting or adjusting medicines.

ICS, inhaled corticosteroid;
LABA, long-acting beta2 agonist;
LAMA, long-acting muscarinic receptor antagonist; **LTRA**, leukotriene receptor antagonist;
MART, maintenance and reliever therapy (using ICS/formoterol combination inhalers); **SABA**, short-acting beta2 agonist.